E. coli strains for producing full-length antibodies
Inventors
Groff, Daniel • Hanson, Jeffrey
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
This disclosure provides methods and compositions related to producing full-length antibodies in E. coli having an oxidative cytoplasm, which is helpful for maintaining the three-dimensional structure and stability of proteins having disulfide bonds. The E. coli is used to produce full length antibody in high yield.
Core Innovation
The disclosed invention is an E. coli cell with an oxidative cytoplasm that expresses full-length antibody heavy and light chains from an expression vector. The vector provides separate ribosome-binding sites for translation of the respective chains, which are not exported outside the cytoplasm. The cell produces more light chain than heavy chain to support the cytoplasmic production and assembly of full-length antibodies.
The supplied text does not include the background section, so the problem being solved is not explicitly described in the patent. Disclosed configurations identify specific DNA sequences for the ribosome-binding sites and describe the incorporation of non-natural amino acids for site-specific payload conjugation. Reported results indicate variations in antibody yield across different expression constructs and compare production between Snuggle and Shuffle strains.
Claims Coverage
The two independent claims cover two inventive features concerning oxidative-cytoplasm E. coli cells that express full-length antibody heavy and light chains.
Cytoplasmic expression of antibody chains
Claim 1 covers an E. coli cell with an oxidative cytoplasm comprising coding sequences encoding full-length antibody heavy and light chains, and an expression vector with separate ribosome-binding sites for translation of each chain. The chains are not exported outside the cytoplasm, and the cell produces more light chain than heavy chain.
Specified ribosome-binding sites for antibody-chain expression
Claim 11 covers an oxidative-cytoplasm E. coli cell comprising an expression vector encoding full-length antibody heavy and light chains. The chains are translated from respective ribosome-binding sites transcribed from specified DNA sequences, and the cell produces more light chain than heavy chain.
The independent claims cover cytoplasmic production of full-length antibody chains in an oxidative-cytoplasm E. coli cell, with greater light-chain than heavy-chain production. Claim 1 specifies cytoplasmic retention without export outside the cytoplasm, while claim 11 specifies DNA sequences for the respective ribosome-binding sites.
Stated Advantages
The patent reports improved IgG titer in Snuggle compared with Shuffle strains and near-complete conjugation efficiency, although the text does not otherwise explicitly characterize these results as advantages.
Documented Applications
Production of full-length antibodies, including B10, H01, 7219, anti-PD1, anti-Tim3, anti-LAG3, anti-Her2, and trastuzumab.
Incorporation of non-natural amino acids at antibody sites for site-specific payload conjugation, including antibody-drug conjugate applications such as conjugation of a B10 antibody product to a drug-linker and PEG8 conjugation of an engineered trastuzumab light chain.
Interested in licensing this patent?